Literature DB >> 10770788

In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis.

J M Rolain1, M Maurin, A Bryskier, D Raoult.   

Abstract

In vitro activities of telithromycin compared to those of erythromycin against Rickettsia spp., Bartonella spp., Coxiella burnetii, and Ehrlichia chaffeensis were determined. Telithromycin was more active than erythromycin against Rickettsia, Bartonella, and Coxiella burnetii, with MICs of 0.5 microg/ml, 0.003 to 0.015 microg/ml, and 1 microg/ml, respectively, but was inactive against Ehrlichia chaffeensis.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10770788      PMCID： PMC89881          DOI： 10.1128/AAC.44.5.1391-1393.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm.

Authors:  M Maurin; A M Benoliel; P Bongrand; D Raoult
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

2.  Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii.

Authors:  D Raoult; H Torres; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 3.  Antimicrobial therapy of rickettsial diseases.

Authors:  D Raoult; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  Randomized trial of doxycycline versus josamycin for Mediterranean spotted fever.

Authors:  F Bella; B Font; S Uriz; T Muñoz; E Espejo; J Traveria; J A Serrano; F Segura
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

5.  Cat-scratch disease. An overview based on a study of 1,200 patients.

Authors:  H A Carithers
Journal:  Am J Dis Child       Date:  1985-11

6.  In vitro susceptibilities of four Bartonella bacilliformis strains to 30 antibiotic compounds.

Authors:  M Sobraquès; M Maurin; R J Birtles; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

7.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates.

Authors:  M Maurin; S Gasquet; C Ducco; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis.

Authors:  P Brouqui; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  Antibiotic therapy for cat-scratch disease?

Authors:  C W Bogue; J D Wise; G F Gray; K M Edwards
Journal:  JAMA       Date:  1989-08-11       Impact factor: 56.272
View more
  11 in total

1.  Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.

Authors:  M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  Use of macrolides for Q fever.

Authors:  Didier Raoult
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 3.  Recommendations for treatment of human infections caused by Bartonella species.

Authors:  J M Rolain; P Brouqui; J E Koehler; C Maguina; M J Dolan; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

4.  Molecular characterization of resistance to macrolides in Bartonella henselae.

Authors:  Silpak Biswas; Didier Raoult; Jean-Marc Rolain
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

5.  Controlled trial of a 5-day course of telithromycin versus doxycycline for treatment of mild to moderate scrub typhus.

Authors:  Dong-Min Kim; Ki Dong Yu; Ji Hyun Lee; Hyun Kuk Kim; Seung-Hyun Lee
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

6.  Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin.

Authors:  D Vazifeh; H Abdelghaffar; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeensis, and Anaplasma phagocytophilum by real-time PCR.

Authors:  S Branger; J M Rolain; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.

Authors:  Jean-Marc Rolain; Areen Boulos; Marie-Noëlle Mallet; Didier Raoult
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 9.  Ehrlichia chaffeensis: a prototypical emerging pathogen.

Authors:  Christopher D Paddock; James E Childs
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

Review 10.  Antibiotics for treatment of resistant gram-positive coccal infections.

Authors:  Hossam Al-Tatari; Nahed Abdel-Haq; Pimpanada Chearskul; Basim Asmar
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 5.319
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.